Opthea
South Yarra · Founded 1984
About Opthea
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
Company Facts
- Founded: 1984
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $500.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: asx:OPT
- Website: http://www.opthea.com/
- Phone: +61398260399
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/opthea-190498 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.